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Abstract
Background: There is a widely recognized need for more pragmatic trials that evaluate interventions in real-world
settings to inform decision-making by patients, providers, and health system leaders. Increasing availability of
electronic health records, centralized research ethics review, and novel trial designs, combined with support and
resources from governments worldwide for patient-centered research, have created an unprecedented opportunity
to advance the conduct of pragmatic trials, which can ultimately improve patient health and health system
outcomes. Such trials raise ethical issues that have not yet been fully addressed, with existing literature
concentrating on regulations in specific jurisdictions rather than arguments grounded in ethical principles.
Proposed solutions (e.g. using different regulations in “learning healthcare systems”) are speculative with no
guarantee of improvement over existing oversight procedures. Most importantly, the literature does not reflect a
broad vision of protecting the core liberty and welfare interests of research participants. Novel ethical guidance is
required. We have assembled a team of ethicists, trialists, methodologists, social scientists, knowledge users, and
community members with the goal of developing guidance for the ethical design and conduct of pragmatic trials.
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Methods: Our project will combine empirical and conceptual work and a consensus development process.
Empirical work will: (1) identify a comprehensive list of ethical issues through interviews with a small group of key
informants (e.g. trialists, ethicists, chairs of research ethics committees); (2) document current practices by reviewing
a random sample of pragmatic trials and surveying authors; (3) elicit views of chairs of research ethics committees
through surveys in Canada, UK, USA, France, and Australia; and (4) elicit views and experiences of community
members and health system leaders through focus groups and surveys. Conceptual work will consist of an ethical
analysis of identified issues and the development of new ethical solutions, outlining principles, policy options, and
rationales. The consensus development process will involve an independent expert panel to develop a final
guidance document.
Discussion: Planned output includes manuscripts, educational materials, and tailored guidance documents to
inform and support researchers, research ethics committees, journal editors, regulators, and funders in the ethical
design and conduct of pragmatic trials.
Keywords: Pragmatic randomized controlled trials, Clinical trials, Research ethics, Informed consent, Usual care
interventions, Patient-centered research, Mixed methods, Ethics guidelines, Comparative effectiveness research,
Large simple trials
Background
Pragmatic versus explanatory trials
Pragmatic trials aim to determine if an intervention
works in real-world settings, so that results can be gener-
alized to everyday practice and support decision-making
by patients, providers, and health system leaders; contrast-
ingly, explanatory trials aim to determine if and how an
intervention works under well-defined and highly con-
trolled conditions [1]. While differences between explana-
tory and pragmatic attitudes in trials were first highlighted
in a seminal article by Schwartz and Lellouch five decades
ago [2], interest in pragmatic trials has increased dramat-
ically in recent years [3]. Accordingly, reporting guidelines
for pragmatic trials have been recently published [4].
In practice, trials are seldom purely pragmatic or
purely explanatory, but various design choices can
make a trial more or less pragmatic. The PRagmatic Ex-
planatory Continuum Indicator Summary (PRECIS-2)
was developed to help trialists identify explicit design
choices that can shift a trial towards being more prag-
matic [5]. PRECIS-2 has nine dimensions along which a
trial can be scored from very explanatory to very prag-
matic. In brief, trials that are more pragmatic have
broader eligibility criteria, recruit participants at the
time of presentation, include a diverse range of settings
that mirror real-world circumstances, do not require
highly specialized training or research personnel, give
healthcare providers flexibility in how the intervention
is delivered, require no special strategy for monitoring
protocol compliance, follow and monitor patients as in
routine clinical practice, have clinically meaningful and
patient-centered outcomes, and include all randomized
patients in analysis.
Explanatory trials, more often conducted on innova-
tive medical products and devices for regulatory
purposes, usually do not fully explicate the benefits
and harms of interventions relative to existing alterna-
tives and hence do not address the central question of
what is likely the best (among the available) options
for particular patients. In contrast, pragmatic trials
test a much wider range of interventions, including
diagnostic, preventive, therapeutic, and delivery sys-
tem interventions. They may test new interventions
against current routine interventions or the compara-
tive effectiveness of different routine interventions
head-to-head. When designed appropriately, they may
address not only whether an intervention works, but
more importantly, for whom and under what condi-
tions. They may test different quality and service
improvement interventions as well as knowledge
translation interventions. Pragmatic trials therefore
offer an important opportunity to improve patient
health and health system outcomes by reducing varia-
tions in care, improving uptake of evidence-based
practice, and reducing costs. For these reasons, the
need for more pragmatic trials has been identified as a
priority by governments worldwide [6–10].
This manuscript presents the study protocol for a
four-year, interdisciplinary, mixed methods research pro-
ject with the ultimate goal to develop internationally ac-
cepted guidance for the ethical design and conduct of
pragmatic trials. Although there are many innovative ob-
servational study designs which can be used to evaluate
interventions and produce new knowledge that informs
decision-making [11], here we focus exclusively on inter-
vention studies that use randomization. We allow for a
broad range of intervention types including diagnostic,
preventive, therapeutic, knowledge translation, and de-
livery system interventions. See Table 1 for a brief gloss-
ary of terms used in this manuscript.
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Ethical issues in pragmatic trials
Trials undertaken in real-world settings raise substantial
ethical issues that have not yet been fully addressed [12–
15]. These ethical issues arise not only from the push to-
wards a greater degree of pragmatism (e.g. along the
nine PRECIS-2 dimensions), but are closely tied to the
types of interventions, as well as the choice of study de-
sign. In addition to established study designs which use
patient randomization (see Example 1 below), pragmatic
trials include some emerging designs and approaches
which capitalize on methodological and statistical inno-
vations as well as the availability of registries and rou-
tinely collected health data (e.g. cohort multiple
randomized controlled designs [16], randomized registry
trials [17], cluster cross-over trials [18], and stepped
wedge cluster randomized trials [18, 19]). The cohort
multiple randomized design and randomized registry tri-
als are examples of pragmatic trial designs that facilitate
the evaluation of usual care interventions embedded
within routine settings, but their ethical implications re-
main unclear. Cluster randomization [20] may be used
to randomize entire medical practices or hospitals to
differing interventions and is a natural choice for evalu-
ating service delivery or other health system level
interventions; however, with the push towards more
pragmatic trials, this design is increasingly being used to
evaluate individual-level interventions (i.e. interventions
that, in theory, could have been evaluated using trad-
itional patient randomized designs). While the Ottawa
Statement on the Ethical Design and Conduct of Cluster
Randomized Trials [21] provides explicit guidance for
cluster randomized trials, the use of this design in the
case of usual care individual-level interventions raises
additional ethical issues (see Example 2 below); more-
over, the stepped wedge cluster randomized design raises
its own unique ethical issues (Example 3).
Table 2 describes a preliminary framework of nine eth-
ical issues; the pragmatic, intervention, and design char-
acteristics that give rise to these issues; and their
potential implications for researchers and research ethics
committees. This framework was developed based on an
initial scoping review [12] and will be further developed
and refined during our project.
Examples of pragmatic randomized controlled trials
For illustrative purposes, we present three examples of
pragmatic trials that raise important ethical issues need-
ing guidance.
Example 1: patient-randomized trial comparing usual care
interventions (SUPPORT)
The SUPPORT trial [22] sought to determine the opti-
mal level of supplemental oxygen on incidence of retin-
opathy of prematurity and mortality in preterm infants.
Infants were randomized to high and low oxygen satura-
tions, both of which fell within the range used routinely
in practice. Lower oxygen levels were found to reduce
retinopathy but increase mortality, leading the authors
to urge caution in their use. In response to an anonym-
ous complaint by parents, the US Office for Human Re-
search Protections launched an investigation into the
trial [23]. It determined that investigators failed to ad-
equately inform parents of “reasonably foreseeable risks”
as consent materials did not list visual impairment and
death as research risks. This incited considerable debate
in the literature [24–27] centered almost exclusively on
considerations of risk and risk communication and
reflecting a preoccupation with US regulations. A central
ethical issue raised by the SUPPORT trial is: Should
usual care interventions be considered part of research or
clinical practice? Other issues raised are: What consti-
tutes usual care? Can a study be considered “minimal
risk” if its endpoints include serious impairments such as
blindness or death? Do parents need to be informed that
their child is participating in a trial? At what level of
detail do the study interventions need to be disclosed to
participants? What potential benefits and harms ought
Table 1 Glossary of terms
Term Definition assumed in this manuscript
Pragmatic trial A trial whose purpose is to evaluate the
effectiveness of an intervention with the
view to informing a decision about a
healthcare policy or practice; key characteristics
are broad eligibility criteria and patient-
centered outcomes to maximize
generalizability and applicability.
Intervention Includes diagnostic, preventive, therapeutic,
and delivery system interventions.
Randomized controlled
trial
A research study in which, using a random
mechanism, human participants are
prospectively assigned (whether as individuals
or in groups) to one or more interventions
(which may include usual care or other
competing interventions), to evaluate the
effects of those interventions on health-related
biomedical or behavioral outcomes.
Usual care
interventions
Treatments or procedures that have been
accepted by medical experts as appropriate
treatments or procedures for a given type of
disease or condition and are commonly used
by healthcare professionals.
Knowledge translation
interventions
An intervention designed to improve the
uptake of research evidence in practice and
reducing barriers and facilitators inherent in
this process.
Gatekeepers Individuals or bodies that represent the
interests of community members,
communities, or organizations participating in
pragmatic trials.
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to be disclosed? What type of research ethics review is
appropriate?
Example 2: cluster randomized registry trial comparing
usual care individual-level interventions implemented as
policy interventions at the cluster-level (FLUID)
The FLUID trial is a pragmatic cluster randomized
cross-over trial comparing resuscitation with Ringer’s
Lactate versus normal saline on death and hospital read-
missions in hospitalized patients, with outcomes
assessed using health administrative data [28]. Both
fluids are considered usual care interventions that have
been available for decades and are administered to many
hospitalized patients. While fluid administration is an
individual-level intervention, the study becomes feasible
only when interventions are implemented as hospital
policies (i.e. at the cluster level) with a waiver of patient
informed consent. In particular, it is essential to have
only one type of study fluid available throughout the
hospital to minimize the risk of contamination due to a
patient receiving both types of study fluids in different
areas of the hospital. It would also be logistically challen-
ging and very costly to recruit and randomize individual
patients within all areas of participating hospitals. In
contrast, the availability of routinely collected data avail-
able for all patients permits the conduct of a very
cost-efficient trial involving hospitals across the prov-
ince, without the need to recruit patients for data collec-
tion. However, the FLUID trial raises several ethical
issues: What is an appropriate justification for adopting
cluster randomization? When individual-level interven-
tions are implemented institution-wide as a policy in a
cluster randomized trial, may one proceed without pa-
tient consent? Do patients need to be notified about the
trial; if so, how? Is consent required for the use of rou-
tinely collected participant data?
Example 3: stepped wedge trial of a quality improvement
intervention (Surgical Checklist Trial)
The Surgical Checklist Trial was a stepped wedge trial
randomizing surgical units in two hospitals in Norway
to evaluate the impact of the World Health Organization
Surgical Safety Checklist on morbidity, mortality, and
length of hospital stay [29]. The stepped wedge design is
characterized by the fact that clusters (here, surgical
units) cross gradually and in random sequence from the
control to the intervention condition, with all clusters
exposed to the intervention by the end of the trial. As
stated by the investigators, the 19-item checklist consists
of an oral confirmation by surgical teams of the comple-
tion of the basic steps for ensuring safe delivery of
anesthesia, prophylaxis against infection, effective team-
work, and other essential practices in surgery. Compli-
ance with the checklist was assessed prospectively by
nurses. All patient outcomes were collected from hos-
pital administrative databases. The regional research eth-
ics committee advised the investigators that the study
was considered clinical service improvement and that re-
search ethics approval and patient informed consent
were not required. The Surgical Checklist Trial raises
several ethical issues: Should trials evaluating quality
and service improvement be considered research? What
are the ethical implications if health system leaders con-
duct (potentially less robust) quality improvement studies
rather than rigorous pragmatic randomized controlled
trials or refrain from conducting important studies due
to perceived ethical barriers? Should health professionals
targeted by study interventions be considered research
participants? If study participation poses no more than
minimal risk, is patient or provider consent required?
What is the harm–benefit balance of exposing all surgi-
cal units to the intervention by the end of the study?
Challenges to the conventional framework for research
ethics
As illustrated by our three examples, pragmatic trials
raise important ethical issues that have not yet been sat-
isfactorily addressed. Existing ethical and regulatory
frameworks were developed primarily for trials with ex-
planatory aims, i.e. focusing on efficacy and safety of ex-
perimental interventions for marketing approval. With
the move towards the conduct of more pragmatic trials,
existing ethics guidance is becoming more difficult to in-
terpret and apply and may not be sufficient to address
these new ethical issues. On the one hand, the absence
of clear guidance may put trials at risk of being accused
of exposing participants to inadequate protections (real
or perceived) (e.g. the SUPPORT trial [23]). It is essen-
tial to avoid undermining the trust that patient commu-
nities have in the research enterprise. On the other
hand, strict enforcement of conventional rules is likely
to pose unnecessary obstacles, undermine scientific
quality or impede improvements in patient health and
health system outcomes. Unless these ethical issues are
addressed, important research with large potential
healthcare benefits may be impeded or may go ahead
without adequate safeguards.
Objectives
The overarching goal of our project is to develop guid-
ance for the ethical design and conduct of pragmatic tri-
als. Specific objectives are to:
1. Systematically identify ethical issues arising from
pragmatic trials;
2. Document ethical practices in completed and
ongoing pragmatic trials;
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3. Elicit views and experiences of trialists,
methodologists, chairs of research ethics
committees, trial participants, and health system
leaders;
4. Develop novel ethical solutions informed by ethical
analyses;
5. Generate ethics guidance through a consensus
process with an independent expert panel;
6. Disseminate tailored guidance to stakeholders.
Methods
Overview
Our project, summarized in Fig. 1, consists of both em-
pirical and conceptual work and concludes with a con-
sensus development process and knowledge translation.
The empirical work, to be completed over the first three
years, consists of five studies:
1. Key informant interviews with a small group of 24–
40 experts;
2. Identification and review of a random sample of
300 completed and ongoing pragmatic trials;
3. Survey of trialists (investigators of the 300
pragmatic trials);
4. Survey of a random sample of chairs of research
ethics committees in Canada, USA, UK, France, and
Australia; and
5. Embedded focus group discussions and a
community survey with trial participants (e.g.
patients) and gatekeepers (i.e. those who have
ability to allow or deny access to trial
participants).
All outputs will inform the ethical analysis in the con-
ceptual work.
Fig. 1 Overview of project phases
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The conceptual work will be an ethical analysis of the
identified ethical issues from the empirical work, resulting
in a series of publications outlining proposed solutions
with principles, policy options, and rationales. The empir-
ical and conceptual work will proceed concurrently to
allow the empirical and ethical analyses to be mutually
informative.
The consensus process, occurring upon completion
of the empirical and conceptual work, will involve
identifying an international expert panel of trialists,
ethicists, chairs of research ethics committees, regula-
tors, funders, and community representatives and or-
ganizing a consensus conference attended by the
panel, as well as invited researchers, representatives
of funding agencies, regulators, journal editors, and
patient and community groups. In addition, we will
engage in e-consultation with the broader research
community, funders, regulators, journal editors, and
patient groups. The panel will produce the final ethics
guidance document which will be disseminated to
stakeholders by the research team.
Empirical studies
Study 1: key informant interviews
The objective of this study is to conduct interviews
with a small group of pragmatic trial experts and
stakeholders (trialists, ethicists, methodologists, chairs
of research ethics committees, health system leaders,
quality improvement experts, and patient representa-
tives on research study teams) to generate a thorough
understanding of types of ethical issues arising in the
practice of pragmatic trials from a variety of perspec-
tives. Informants will be selected using a purposive
sampling strategy, augmented through snowball sam-
pling. Potential interviewees will be selected across a
broad range of jurisdictions and clinical areas to re-
flect a range of experiences, including lower- and
middle-income countries. The sample size will be de-
termined to ensure representation from all targeted
stakeholders and by when saturation is reached (i.e.
when new interviews cease to provide fresh informa-
tion) [30–34]. Based on our prior experience with
similar studies [35], we anticipate that 24–40 inter-
views will be required. Interviews are expected to last
1 h and will be audio recorded. A semi-structured
interview guide will allow participants to respond
freely, to illustrate concepts, and to present perspec-
tives that the interviewer can probe further. To moni-
tor the progress of the interviews and permit
follow-up of issues that may emerge from the data,
interviewing, transcription, and analysis will proceed
concurrently. The interview guide may evolve as a
typology of ethical issues begins to emerge. Record-
ings will be transcribed and verified before analysis.
Data will be imported into a qualitative software
package (NVivo 11) to facilitate thematic coding,
evaluation, and analysis. The results will be used to
formulate a typology of ethical issues arising from
pragmatic trials, to be addressed in the conceptual
work. It will also inform data extraction and ques-
tionnaire items for studies 2–5.
Study 2: review of published trials
The objectives of this study are to select and review a
random sample of recently completed and ongoing
trials that have more pragmatic (than explanatory)
aims, to describe ethical characteristics, identify eth-
ical challenges reported, the circumstances under
which they arise, and how they are being addressed.
We anticipate challenges in identifying a sample of
“pragmatic” trials given wide variation in definitions
and inconsistent and unreliable reporting of trial de-
sign. We will develop objective and reproducible cri-
teria to characterize a trial as having pragmatic aims,
as well as the conditions under which those criteria
apply. We will work with an information scientist to
develop a sensitive and specific electronic search
strategy to identify a sample of trials. To develop and
validate an electronic search strategy, we will use a
multi-pronged approach to identify a gold standard
set of trials meeting our criteria for testing the search
strategy, including: (1) pragmatic trials conducted by
the investigator team and our extensive networks; (2)
pragmatic trials identified in the key informant inter-
views; (3) databases of funded pragmatic trials in
Canada, the USA, UK, France, and Australia; (4) a
database of pragmatic trials maintained by the PRE-
CIS group [36]; (5) demonstration projects by the Na-
tional Institutes of Health Collaboratory [37] and
PCORnet [38]; and (6) trials included as exemplars in
recent publications about pragmatic trials. The pro-
portion of these pragmatic trials retrieved by the
search strategy will be calculated and used to refine
the search strategy if necessary as done in our previ-
ous work [39]. Once validated, the search strategy will
be used to select a random sample of 300 pragmatic
trials. As the ethical landscape may have been chan-
ging in recent years, we will include completed trials
as well as study protocols for ongoing trials. Eligibility
criteria, to be refined, will include trials or study pro-
tocols published in the past five years by investigators
in Canada, UK, USA, France, and Australia, including
trials conducted in lower- and middle-income coun-
tries. Items for extraction will be generated based on
team discussion and key informant interviews. After
pilot testing, two reviewers will independently extract
data from each trial report. Discrepancies between re-
viewers will be identified and resolved by discussion
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with a third reviewer if required. Prevalence of ethical
issues and practices arising from pragmatic design
features, study design, and type of study interventions
will be described overall and within subgroups of
interest where feasible (e.g. over time, between coun-
tries, study sponsors). Methodological and reporting
quality of the included trials will be collected and
evaluated against major methodological and reporting
criteria as done in our previous work [40, 41]. The
preliminary ethics framework will be updated as ex-
tractions proceed.
Study 3: survey of trialists
The objective of this study is to gather more detailed infor-
mation about practices and experiences identified in our re-
view of pragmatic trials. After pilot testing, we will
administer a survey consisting of open- and closed-ended
items to corresponding authors of the sample of 300 trials.
The primary mode of survey administration will be
web-based, but alternatives (paper, telephone) will be con-
sidered to increase the response rate. A series of contacts
(pre-notifications, notifications, and reminders) based on
Dillman’s recommendations for the implementation of mail
and Internet surveys will be used [42]. The survey will be
used to characterize the ethical conduct, review, and report-
ing of pragmatic trials from the perspectives of trialists. We
will offer respondents a $30 gift certificate or donation on
behalf of the respondent in appreciation for their time. We
will use questionnaire personalization—a previously pub-
lished methodology developed by our team—to gather
more detailed information about aspects of the published
trial [43]. The anticipated response rate, based on previous
experience with this population and methodology, is 65%
[44]. Results from the survey will be compared to results
from the published trial to assess adequacy of reporting of
ethical issues and to describe implications of design choices
(e.g. impact of alternative consent models on study recruit-
ment and risks of selection bias). Potential non-response
bias will be assessed by comparing characteristics of re-
spondents and non-respondents using information in trial
reports. We will describe the use of gatekeepers (i.e. indi-
viduals or bodies that represent the interests of community
members, communities, or organizations [45]), use of con-
sent waivers or alternative consent models (e.g. “stream-
lined consent” [12]), and details about information
conveyed to participants in each study arm. We will de-
scribe the type of ethics review required, perceived impact
on the timing of implementation, ethical and scientific
quality of the trial, and uniformity of process and decisions
in multicenter trials. We will explore the possibility of
requesting informed consent documents and research eth-
ics application forms and protocols for a subset of trials.
Results will inform the ethics framework for analysis in the
conceptual work.
Study 4: survey of research ethics committee chairs
The objective of this study is to gather information on
the views, practices, and experiences of research ethics
committee chairs in Canada, the USA, UK, France, and
Australia. We will aim to select all research ethics com-
mittees that review clinical trials in Canada (approxi-
mately 200), the UK (approximately 100), Australia [46]
(approximately 200), France (approximately 39) [47],
and a random sample of 200 from over 9000 Institu-
tional Review Board Organizations in the USA [48]. We
chose these five countries primarily based on logistical
considerations: our team members have connections
with research ethics organizations in these countries
which will help facilitate participation. Canada does not
maintain a list of research ethics committees. We will
use a strategy previously developed by our team to
identify eligible committees [49]. It involves integrating
internet searches with a list of Institutional Review
Board Organizations maintained by the US Office of
Human Research Protections. Given that biomedical
and non-biomedical Institutional Review Boards are
not differentiated in this list, we will use stratification
by National Institutes of Health funding levels to in-
crease the efficiency of identifying Boards with relevant
experience reviewing clinical research.
Questionnaire items will be informed by the prelimin-
ary ethics framework, key informant interviews, and re-
sults from the trialist survey. Questionnaires will consist
of open- and closed-ended items and include a series of
scenarios. After pilot testing, a series of contacts (notifi-
cations and reminders) based on Dillman’s recommen-
dations for Internet surveys will be used [42]. We will
likely encounter challenges in ensuring an adequate
response rate; based on previous experience with survey-
ing this population, we expect a response rate of
approximately 35% [49]. We will deliberately keep ques-
tionnaires short and adhere to recent recommendations
for improving response rates [42]. Results will be
summarized using descriptive statistics and compared
across subgroups (e.g. country, size and type of commit-
tee, years of experience). Where feasible, potential
non-response bias will be assessed by comparing charac-
teristics of respondents and non-respondents using in-
formation on research ethics committee websites.
Questionnaires will be prepared in both English and
French. Open-ended responses will be analyzed themat-
ically. Results will inform the ethics framework for ana-
lysis in the conceptual work and knowledge translation
activities to research ethics committees.
Study 5: focus group discussions and community survey
The objective of this study is to gather information on
the views and experiences of trial participants or pro-
spective trial participants (e.g. patients), gatekeepers
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(organizational leadership, medical directors), and
communities. Our research team members are in-
volved in 15–20 pragmatic trials at any one time. We
will identify one ongoing or recently completed prag-
matic trial in each country, ensuring a range of types
of pragmatic trials. We will conduct focus groups with
eligible trial participants (with permission from the re-
sponsible research ethics committees and the chief in-
vestigator). We anticipate five focus groups with
patients and five with gatekeepers. Focus groups will
be 1–2 h in length and involve six participants per
group. A semi-structured discussion guide will be used
to gather information on participants’ experiences
with the trial including recruitment, informed consent,
perceived benefits and harms, any privacy concerns,
and satisfaction with the trial. Among eligible pro-
spective participants, we will explore potential reasons
for non-participation. Discussions will be recorded,
transcribed verbatim, and verified by the facilitator be-
fore analysis in NVivo 11 [50]. To monitor progress
and permit follow-up of issues that may emerge from
the data, discussions, transcription, and analysis will
proceed concurrently [51]. For focus groups not con-
ducted in French, interview guides will be developed
in English by the study team and then translated into
French by bilingual members of the research team. To
verify the accuracy of the translation, all guides will be
independently back-translated. All focus group discus-
sions will be transcribed in the language in which the
group was conducted. Non-English transcripts will be
translated into English and then independently
back-translated to the original language. A Canadian
pragmatic trial will be used to design a survey of com-
munity members targeted by the trial (e.g. diabetes pa-
tients, hospital patients). Quantitative and qualitative
analyses will be used to summarize results from the
community survey. Results will be used to inform the
ethical analysis in the conceptual work.
Ethical analysis
The ethical analysis will be an intensive process run
concurrently with the empirical work and will extend
over a period of three years. Conceptual work in bio-
ethics is not amenable to the degree of a priori meth-
odological specification that is expected of empirical
research. Reproducibility is an indispensable feature of
rigorous science, necessitating the clear statement of
hypotheses and experimental methods upfront. Rigor-
ous conceptual work in ethics begins with the articu-
lation of clear and important questions and is realized
in the construction of careful and clear analysis of
the relevant concepts and of ethical arguments in
peer-reviewed publications and policy reports [52].
The ethical analysis in this project will be based on
an evolving framework of ethical issues developed
using results from an extensive literature search con-
ducted in preparation for this proposal (see Table 2)
and revised using results from the five empirical stud-
ies. For each identified set of core ethical issues, an
in-depth and written ethical analysis will be prepared.
An extensive review of the scholarly literature will
document and critically analyze arguments proffered
for and against ethical positions. The ethical analysis
will seek to synthesize foundational documents, regu-
lations, and arguments in the literature into a coher-
ent solution. Where disagreement among the various
sources cannot be resolved by critical analysis, the
contours of the ethical dispute will be documented.
The ethical analysis will result in a series of back-
ground documents laying out proposed solutions with
principles, policy options, and rationale and will also
be submitted for peer-reviewed publication. These
documents will be used as background materials in
the consensus process.
Expert panel and consensus process
An international expert panel will be convened to de-
velop ethics guidance. The composition of the panel is
expected to be 4–6 pragmatic trialists and methodolo-
gists, 4–6 ethicists and chairs of research ethics com-
mittees, 2–4 quality improvement experts and health
system leaders, 1–2 regulators, 1–2 journal editors, and
2–4 community members. No more than one-third of
the members of the panel will be drawn from the re-
search team and adequate representation from a broad
range of countries including lower- and middle-income
countries will be sought. The panel will be provided
with output from the empirical studies as well as the
documents prepared during the ethical analysis one
month in advance of a three-day consensus conference
which will also be attended by invited researchers and
representatives from major funding bodies, regulators,
journal editors, and community groups. The conference
will consist of both open and closed sessions. At the
open sessions, proposed ethics guidance with support-
ing ethical analysis will be presented by the research
team and comments and discussion invited from at-
tendees. The panel will then meet in closed sessions to
discuss and formulate draft guidance. Based on previ-
ous experience with the consensus process [21], we an-
ticipate that at the beginning of the meeting, the panel
will set rules for debate, handling of disagreements, and
how to achieve consensus. We do not expect to use a
majority voting system but anticipate that agreement
will be reached through discussion, with documentation
of disagreements where they exist. After the meeting, a
draft guidance document will be produced by a writing
committee and refined after further discussion with the
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panel. An e-consultation process will be launched to invite
comments from the broader research community, fun-
ders, regulators, journal editors, and community groups.
Based on results from this process, the writing committee
will make revisions and produce the final consensus
guidance.
Discussion
The goal of our international, interdisciplinary collabor-
ation is to develop, publish, and promote the uptake of
guidance for the ethical design and conduct of prag-
matic randomized controlled trials. We seek to create a
novel approach to the ethics of pragmatic trials that im-
proves upon the existing literature, which has been crit-
icized for lacking convincing arguments grounded in
ethical principles [53], including claims based on erro-
neous assumptions [54], appealing mainly to regula-
tions in particular jurisdictions [55–57], offering
speculative solutions with no guarantee of improve-
ment over existing oversight procedures [58], and fail-
ing to reflect a broad vision of protecting the liberty
and welfare interests of research participants [59]. The
proposed process is informed and enriched by our pre-
vious experience with developing ethics guidance for
cluster randomized trials [21, 60]. The planned output
includes manuscripts, educational materials, and tai-
lored guidance documents. Our proposed project is
novel in that it: (1) involves close collaboration between
clinical trialists, ethicists, and methodologists; (2) com-
bines concurrent empirical and ethical analysis in a mu-
tually informative approach; (3) integrates views and
experiences of stakeholders (e.g. trialists, chairs of re-
search ethics committees, health system leaders, com-
munity members); and (4) aims to generate guidance
rooted in internationally accepted ethical principles ra-
ther than regulation specific to one jurisdiction. We ex-
pect that the study outputs will be of interest to a wide
range of knowledge users including trialists, healthcare
professionals, ethicists, research ethics committees,
journal editors, regulators, health system leaders, re-
search funders, and patient groups. Guidance will facili-
tate the conduct of research important to patients,
clinicians, and the healthcare system, while upholding
the highest ethical standards in research. While the
scope of the planned guidance is intended to be inter-
national, some of the empirical studies (e.g. focus
groups) will be geographically restricted based on logis-
tical and feasibility considerations.
Our knowledge translation strategy will be guided by
the Canadian Institutes of Health Research Guide to
Knowledge Translation Planning [61]. We will use our
considerable informal networks nationally and inter-
nationally to disseminate our findings. Work stem-
ming from the research will be submitted for
presentation at national and international conferences
and meetings targeting specific stakeholder groups
(e.g. journal editors, funders, regulators). The final
ethics guidance document will be published in a major
journal with summaries published simultaneously in
other major journals. Educational material for re-
searchers and research ethics committees will be de-
veloped. Social media will be used to communicate
results to the public.
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